Praxis Precision Medicines, Inc. - Common Stock (NQ:PRAX)

295.51 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Praxis Precision Medicines, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

February 19, 2026

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

MoonLake Stock Soars As Biotech Fund Reloads, Takeover Chatter Ignites ↗

February 17, 2026

Optimism also grew around FDA momentum for its palmoplantar pustulosis drug ahead of MoonLake’s Feb. 23 investor day.

Via Stocktwits

Biotech Stock Up 266%: This New $55 Million Bet Signals Conviction in Praxis Amid Pipeline Progress ↗

February 14, 2026

Praxis Precision Medicines develops therapies for central nervous system disorders, with candidates targeting depression and epilepsy.

Via The Motley Fool

Topics Regulatory Compliance

Soleus Adds a Significant Number of Celcuity Shares ↗

February 13, 2026

This clinical-stage biotech develops targeted cancer therapies and diagnostics using proprietary technology for personalized treatment.

Via The Motley Fool

Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences

February 09, 2026

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 04, 2026

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

The Biotech Renaissance: Scientific Breakthroughs and M&A Frenzy Spark a New Bull Market

January 22, 2026

The U.S. biotech sector has officially entered a new golden age. As of January 22, 2026, the industry is witnessing a "renaissance" that has effectively erased the memories of the grueling three-year...

Via MarketMinute

Topics Artificial Intelligence ETFs Initial Public Offering

Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy

January 13, 2026

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of Progress

January 12, 2026

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 09, 2026

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments

January 08, 2026

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering

January 06, 2026

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Praxis Precision Medicines, Inc. Announces Proposed Public Offering

January 06, 2026

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Why Praxis Precision Medicines Stock Popped Today ↗

December 29, 2025

A medical breakthrough is shining a light on the biotech's promising development platform.

Via The Motley Fool

Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal

December 29, 2025

The biopharmaceutical sector witnessed a dramatic surge in volatility today, December 29, 2025, as the industry careened toward the end of its strongest year in two decades. In a day defined by extreme...

Via MarketMinute

Topics ETFs Intellectual Property

Praxis Stock Surges On FDA Breakthrough Status For Essential Tremor Drug ↗

December 29, 2025

Praxis Precision Medicines Inc (NASDAQ: PRAX) stock rose after FDA granted BTD for ulixacaltamide to treat essential tremor.

Via Benzinga

Traders are paying attention to the gapping stocks in Monday's session. ↗

December 29, 2025

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday.

Via Chartmill

Why Did Praxis Precision Stock Surge 12% Pre-Market Today? ↗

December 29, 2025

The Breakthrough Therapy Designation designation for ulixacaltamide was granted after positive topline results from the Essential3 program, which included two Phase 3 studies.

Via Stocktwits

Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor

December 29, 2025

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026

December 11, 2025

EMBOLD data to serve as basis of efficacy and safety following discussion with the FDA

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Praxis Precision Medicines Announces Alignment with FDA on Simplified and Accelerated Registrational Pathway for Elsunersen in Early Onset SCN2A Developmental and Epileptic Encephalopathy

December 09, 2025

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Praxis AES Wrap-up: Best-in-Class Potential Across Rare Pediatric and Adult Epilepsies

December 08, 2025

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

What's going on in today's session ↗

December 05, 2025

Wondering how the US markets performed one hour before the close of the markets on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.

Via Chartmill

Top movers analysis in the middle of the day on 2025-12-05: top gainers and losers in today's session. ↗

December 05, 2025

Keep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements.

Via Chartmill

The market is filled with gapping stocks in Friday's session. ↗

December 05, 2025

Let's have a look at what is happening on the US markets on Friday. Below you can find the gap up and gap down stocks in today's session.

Via Chartmill

What's going on in today's pre-market session ↗

December 05, 2025

Before the opening bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.

Via Chartmill

Why Did PRAX Stock Rocket 24% Pre-Market Today? ↗

December 05, 2025

The Data Monitoring Committee (DMC) recommended stopping the EMBOLD study ahead of schedule after the interim analysis demonstrated strong positive outcomes.

Via Stocktwits

Praxis Precision Medicines Stock Surges 25% In Friday Pre-Market Trading— What's Going On? ↗

December 05, 2025

Praxis Precision Medicines Inc. (NASDAQ: PRAX) shares surged 24.81% in pre-market trading on Friday, climbing to $237.10— what's going on?

Via Benzinga

Nasdaq, S&P 500 Futures Set For Firm Open Ahead Of PCE Inflation Data: Why NFLX, SMX, SOFI, IOT Are On Traders' Radar ↗

December 05, 2025

Retail sentiment, however, remains cautious, with SPY and QQQ flashing bearish on Stocktwits.

Via Stocktwits

Topics Artificial Intelligence ETFs Economy

Curious about the stocks that are showing activity after the closing bell on Thursday? ↗

December 04, 2025

As the regular session of the US market concludes on Thursday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.